Publications

View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.

Literature Highlights

Publications

Clear Search

Showing 1 result for “Ankylosing spondylitis; Biologic; Inadequate response; Janus kinase inhibitor; Open-label extension; Refractory; Tumor necrosis factor; Upadacitinib”.

October 2023
Publication thumbnail: Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study View Slides

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study

, , , , , , , , , ,

Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

more…

Keywords: